Joris Delanghe
University of Minnesota
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joris Delanghe.
Atherosclerosis | 2003
Michel Langlois; Dirk De Bacquer; Daniel Duprez; Marc L. De Buyzere; Joris Delanghe; Victor Blaton
BACKGROUND Uric acid is frequently elevated in hypertension. In addition to renal and metabolic disturbances, lower limb ischemia might contribute to hyperuricemia among hypertensives complicated by peripheral arterial disease (PAD). OBJECTIVE To test the hypothesis that uric acid status is related to lower limb function in hypertensives with PAD. METHODS Serum and 24-h urine uric acid levels and other risk factors were examined in 145 hypertensives free of PAD and 166 hypertensives with PAD. Ankle/brachial index (ABI) and absolute claudication distance (in PAD) on a treadmill test (ACD) were assessed. RESULTS In multiple regression analysis for serum uric acid in the total group, PAD emerged as an independent determinant (P=0.03) next to age (P=0.005), triglycerides (P=0.04), and insulin (P=0.02). Serum uric acid concentrations were higher in hypertensives with PAD (404+/-101 vs. 347+/-80 micromol/l, P<0.001) independent of components of the metabolic syndrome (body mass index, triglycerides, insulin) and of age, gender, diabetes mellitus, pulse pressure, cholesterol, C-reactive protein, and treatment. After adjustment for kidney function by uric acid/creatinine ratio, values remained higher in hypertensives with PAD (P=0.01). Uric acid excretion was higher in the PAD group (P<0.001), whereas uric acid clearance was comparable between both groups. In multiple regression analysis for ACD (357+/-183 m) in the PAD group, serum uric acid (P=0.02), C-reactive protein (P<0.0001), age (P=0.02), and smoking (P=0.004) were independently associated. ABI (0.62+/-0.17) was not related to uric acid in PAD patients. CONCLUSION Hyperuricemia is more pronounced in hypertensives complicated by PAD and is associated with worse functional status of the peripheral circulation.
Archive | 1998
Joris Delanghe; Michel Langlois; Buyzere Marc L De
Archive | 2012
Thomas M. Maenhout; Guido Baten; Marc De Buyzere; Joris Delanghe
Journal of Biomedical chromatography | 1998
Jin Ouyang; Joris Delanghe; Willy Baeyens; Michel Langlois
European Journal of Laboratory Medicine , 4 pp. 55-59. (1996) | 1996
Joris Delanghe; Jp Deslypere; Marc De Buyzere; S De Biscop; P Willems; A Walker
Biologie prospective -Comptes rendus du 9e colloque de Pont-à-Mousson. John Libbey Eurotext, Paris 1997 | 1997
Joris Delanghe; Michel Langlois; Marc De Buyzere; Daniel Duprez
Advances in critical care testing (List WF, Mueller MM, McQueeen MJ, eds). Springer Verlag, Berlin-Heidelberg-New York 1997:p. 86-87 | 1997
Dirk Bernard; Michel Langlois; Marc De Buyzere; Joris Delanghe
Archive | 1996
Michel Langlois; Joris Delanghe; Marc Dc Buyzere
Pathobiochemie, Molekularbiologie und moderne Diagnostik kardiovaskulärer Erkrankungen' Springer Verlag, Berlin-Heidelberg | 1994
Joris Delanghe; Marc De Buyzere
ISSN: 0009-7322 | 1994
Marc De Buyzere; D Robbrecht; Joris Delanghe; Daniel Duprez; Denis Clement